Drugs / isobutylamido-thiazolyl-resorcinol
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05119413 | Nov 2021 → Sep 2022 | hyperpigmentation of the skin | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07676994 | May → Dec 2025 | hyperpigmentation of the skin | Ghurki Trust and Teaching Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | isobutylamido-thiazolyl-resorcinol | “New trio combination is a drug containing 0.1% isobutylamido-thiazolyl-resorcinol, 0.1% retinoic acid and 0.1% dexamethasone” NCT07676994 ↗ |
| Known as | Thiamidol | “Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile.” NCT05119413 ↗ |